KIKUCHI Noriko
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor |
|
Language | English |
Title | Renal Function and the Prognostic Impact of Renin-angiotensin-aldosterone System Inhibitors for Heart Failure Patients: An Analysis of HIJ-HF II Study |
Conference | The 83rd Annual Scientific Meeting of the Japanese Circulation Society (JCS2019) |
Promoters | Japanese Circulation Society |
Conference Type | Nationwide Conferences |
Presentation Type | Speech |
Lecture Type | General |
Publisher and common publisher | ◎SUZUKI Keisuke, OYABU Kenjiro, SUZUKI Atsushi, MATSUI Yuko, NAGARA Kimiko, HARUKI Shintaro, KIKUCHI Noriko, HATTORI Hidetoshi, WATANABE Erisa, SUZUKI Tsuyoshi, SHIGA Tsuyoshi, HAGIWARA Nobuhisa |
Date | 2019/03/29 |
Venue (city and name of the country) |
Yokohama, JAPAN |
Summary | *Featured Research Session 4 (HF/CM) Heart Failure, Cardiomyopathy (Clinical)
Angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) reduce mortality and morbidity in patients with heart failure (HF). The aim of this study was to assess the impact of ACE-I or ARB on mortality among HF patients with and without renal dysfunction. After the exclusion of patients receiving regular hemodialysis, 536 HF patients discharged alive (age: 70±15 years, 34% female) from a multicenter hospital-based cohort consisted of HF patients between 2013 and 2014 were studied. Renal dysfunction was defined estimated glomerular filtration rate <60 mL/min/1.73 m2. During 17±10 months follow-up, there was a tendency that the mortality rate was higher in patients with renal dysfunction compared without renal dysfunction (18% vs. 13%). Although the mortality was significantly lower in ACE-I/ARB patients than nonACE-I/ARB patients among patients without renal dysfunction (Figure A), there was no difference in mortality between ACE-I/ARB and non-ACE-I/ARB patients among patients with renal dysfunction (Figure B). The effect of ACE-I/ARB on mortality might be difference in HF patients with and without renal dysfunction. |